Geron Corp Dossier - Source-backed chat

Geron Corp

GERNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.73

Intrinsic Value $1.22median of 2 methodsbased on filings through 31 Dec 2025

Market Price $1.21Price as of 1 Oct 2026

Near fair valueIntrinsic value is 1% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $777.4M

Enterprise Value $949.8M

Shares Outstanding 641.5M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Geron Corporation has successfully transitioned into a commercial-stage biopharmaceutical company following the FDA and EU approvals of its first-in-class telomerase inhibitor, RYTELO (imetelstat), for lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. While the stock has experienced downward pressure due to a perceived flat commercial ramp-up in late 2025, Q1 2026 results demonstrate a positive inflection with net product revenues rising to $51.8 million (an 8% sequential increase). Backed by a strong cash position of $341 million and a streamlined cost structure following a one-third workforce reduction in late 2025, Geron is well-positioned to meet its 2026 revenue guidance of $220M–$240M. The primary near-term catalyst is the event-driven interim overall survival analysis of the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis expected in H2 2026, which represents a major expansion opportunity.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$4.25

High · most bullish analyst$6.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

RYTELO sales growth stalls in the U.S. due to intense competition and rising gross-to-net adjustments (exceeding the mid-twenties percentage range), causing the company to miss its 2026 revenue guidance. Additionally, the IMpactMF interim analysis in H2 2026 fails to show a meaningful survival benefit or reveals unfavorable safety signals, severely damaging the pipeline's expansion prospects and accelerating cash burn.

Base CaseCentral scenario

RYTELO continues its steady commercial ramp-up in the U.S., supported by its inclusion in the NCCN Chemotherapy Order Templates and expanded medical education. The company successfully achieves its 2026 net product revenue guidance of $220M–$240M while keeping operating expenses disciplined within the $230M–$240M range. The IMpactMF interim analysis in H2 2026 shows positive survival trends, keeping the trial on track for final readout in 2028 and validating the long-term potential of imetelstat in myelofibrosis.

Bull CaseUpside scenario

The bull case for Geron is centered on the commercial acceleration of Rytelo (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) following its FDA approval, alongside potential label expansion into myelofibrosis (MF) via the ongoing Phase 3 IMpactMF trial. Analysts project that successful commercial execution and positive clinical readouts could drive significant revenue growth, with consensus price targets reaching up to $4.00 to $5.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class approved telomerase inhibitor (RYTELO) with established FDA and EU approvals in lower-risk MDS.
Inflection in Q1 2026 commercial performance with $51.8 million in net product revenue, representing 8% sequential growth.
Strong balance sheet with $341 million in cash and marketable securities, providing a solid runway to execute commercial and clinical plans.
High-impact clinical catalyst in H2 2026 with the Phase 3 IMpactMF interim overall survival analysis in relapsed/refractory myelofibrosis.

Key Investment Risks

Commercial execution risk if RYTELO fails to sustain demand growth or faces higher-than-expected gross-to-net discounts.
Clinical trial risk associated with the event-driven IMpactMF interim analysis, where failure to show survival benefit would limit market expansion.
Regulatory and reimbursement hurdles in European markets that could delay international revenue contribution.

Thesis Invalidation Triggers

RYTELO quarterly net product revenues flatlining or declining below $50 million in subsequent 2026 quarters.
Negative efficacy or safety signals from the IMpactMF interim analysis leading to trial termination or significant delays.
Operating expenses significantly exceeding the guided $230M–$240M range, accelerating cash burn.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.